Scarica l'app Stockscreener
1.19
2.46%
-0.03
Dopo l'orario di chiusura:
1.19
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MXCT Giù?
Forum
Previsione
Precedente Chiudi:
$1.22
Aprire:
$1.22
Volume 24 ore:
300.46K
Relative Volume:
0.29
Capitalizzazione di mercato:
$122.82M
Reddito:
$32.29M
Utile/perdita netta:
$-39.12M
Rapporto P/E:
-3.2434
EPS:
-0.3669
Flusso di cassa netto:
$-29.51M
1 W Prestazione:
-5.56%
1M Prestazione:
-1.65%
6M Prestazione:
+50.86%
1 anno Prestazione:
-16.20%
Intervallo 1D:
$1.18
$1.23
Intervallo di 1 settimana:
$1.18
$1.30
Portata 52W:
$0.6434
$1.865
Maxcyte Inc Stock (MXCT) Company Profile
Nome
Maxcyte Inc
Settore
Industria
Telefono
301-517-5556
Indirizzo
9713 KEY WEST AVENUE,, ROCKVILLE
Compare MXCT vs ABT, MDT, SYK, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MXCT
Maxcyte Inc
|
1.19 | 125.91M | 32.29M | -39.12M | -29.51M | -0.3669 |
ABT
Abbott Laboratories
|
103.36 | 182.09B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
91.62 | 117.54B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
270.01 | 105.63B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
43.10 | 65.16B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.77 | 49.67B | 6.30B | 1.07B | 1.09B | 1.8406 |
Maxcyte Inc Stock (MXCT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-11 | Downgrade | BTIG Research | Buy → Neutral |
| 2025-08-07 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-07-22 | Iniziato | Stephens | Overweight |
| 2023-11-29 | Iniziato | Craig Hallum | Buy |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-08-24 | Iniziato | BTIG Research | Buy |
| 2021-08-24 | Iniziato | Cowen | Outperform |
| 2021-08-24 | Iniziato | Stephens | Overweight |
| 2021-08-24 | Iniziato | Stifel | Buy |
| 2021-08-24 | Iniziato | Wedbush | Outperform |
| 2021-08-24 | Iniziato | William Blair | Outperform |
Mostra tutto
Maxcyte Inc Borsa (MXCT) Ultime notizie
MaxCyte Inc (NASDAQ: MXCT) Stock Price, News & Analysis - Kalkine
MXCT stock holds steady as MaxCyte focuses on cell-therapy growth - ad-hoc-news.de
MXCT stock holds steady as MaxCyte prepares next growth steps - ad-hoc-news.de
MXCT Q2 2026 Earnings: Narrower-Than-Expected Loss Lifts Shares 2.42%Share Dilution Risk - vinanet.vn
MaxCyte Inc. (MXCT) Peer Comparison – Compare with Others - valueresearchonline.com
MaxCyte stock rating held at Neutral by BTIG after Q2 results - Investing.com India
MaxCyte (MXCT) Q2 2026 Earnings: EPS Comes in Above Forecast in the Latest Reading; Market Reaction - vinanet.vn
MaxCyte Gets A Genentech Nod, But Revenue Still Comes In Chunks - Finimize
MaxCyte launches base editor off-target nomination assays By Investing.com - Investing.com Nigeria
MaxCyte (MXCT) Earnings Reading: EPS Prints Above Forecast in the Latest Session; Stock Move - vinanet.vn
MaxCyte launches base editor off-target nomination assays - Investing.com
MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies - The Manila Times
MaxCyte launches a gene-editing test that sees population-specific DNA variants - Stock Titan
MaxCyte, Inc. Revenue Breakdown – NASDAQ:MXCT - TradingView
MaxCyte(MXCT) Stock Options Chain | Quotes & News - Moomoo
MXCT Q2 2026 Earnings: Narrower-Than-Expected Loss Marks a 15.97% EPS Beat, Yet Shares Slip 5.04%Earnings Sentiment Score - vinanet.vn
Teleconferência de Resultados do 2T26 da MaxCyte (MXCT): Guidance Reafirmado com a Expansão da Parceria com a Genentech - TradingKey
Conferencia de resultados del T2 de 2026 de MaxCyte (MXCT): Se reafirman las proyecciones a medida que se amplía la alianza con Genentech - TradingKey
MaxCyte, Inc. Releases Q2 2026 Results: Cell Engineering Platform Momentum in FocusRevenue Inflection Point - dars.gov.et
MaxCyte (MXCT) Earnings Call Q2 2026: Prognose bekräftigt bei Ausbau der Genentech-Partnerschaft - TradingKey
MaxCyte (MXCT) Q2 2026 Earnings Call: Guidance Reaffirmed as Genentech Partnership Expands - TradingKey
Stifel Nicolaus Keeps Their Buy Rating on MaxCyte (MXCT) - The Globe and Mail
TD Cowen Maintains MaxCyte(MXCT.US) With Buy Rating - Moomoo
MaxCyte revenue down 15% to USD 7.3M in Q2 2026 - medicalbuyer.co.in
MaxCyte, Inc. $MXCT Shares Acquired by Renaissance Technologies LLC - MarketBeat
Price to sales forward of MaxCyte, Inc. – MUN:MYE0 - TradingView
MaxCyte Inc (MXCT) (Q2 2026) Earnings Call Highlights: Strategic Pivot to Enterprise ... - Yahoo! Finance Canada
MXCT Looks 49.6% Undervalued on GF Value™ - GuruFocus
MaxCyte, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
MaxCyte Q2 Earnings Call Highlights - MarketBeat
MaxCyte (NASDAQ:MXCT) Issues Earnings Results - MarketBeat
MaxCyte affirms FY26 sales guidance of $30M-$32M vs estimate - scanx.trade
MaxCyte, Inc. (MXCT) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Earnings call transcript: MaxCyte tops Q2 2026 revenue forecast, shares fall - Investing.com
MaxCyte Reports Q2 Results, Highlights Genentech Partnership - TipRanks
MaxCyte Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Maxcyte, Inc. Provides Earnings Guidance for the Back Half of 2026 and Reiterates Earnings Revenue Guidance for the Full Year 2026 - marketscreener.com
Tranche Update on MaxCyte, Inc.'s Equity Buyback Plan announced on May 12, 2026. - marketscreener.com
MaxCyte Reports Second Quarter 2026 Financial Results - The Manila Times
MXCT Q1 2026 Earnings: EPS Surprise of 50.98% Delivers Narrower Loss, Shares Rise 2.48%Earnings Analysis - Vinanet
RIVER GLOBAL INVESTORS LLP Trims MaxCyte Inc (MXCT) Stake -- Shares Trade at 52% Discount to GF Value - GuruFocus
MaxCyte Inc expected to post a loss of 9 cents a shareEarnings Preview - TradingView
MaxCyte (MXCT) Q1 2026 Earnings: Narrower Loss Beats Estimates as Shares Rise 6.31%Financial Summary - dars.gov.et
MaxCyte (MXCT) Climbs 6.3% to $1.18 as Cell Engineering Momentum BuildsIchimoku Kumo Twist - dars.gov.et
Earnings Preview: MaxCyte to Report Financial Results Post-market on August 12 - Moomoo
MaxCyte | 4: Statement of changes in beneficial ownership of securities-Director Johnston John Joseph - Moomoo
Latest MXCT ETF News Today | Earnings, Events & Price Alerts - Intellectia AI
MaxCyte (MXCT) Expected to Post Earnings on Wednesday - MarketBeat
River Global Investors Discloses Investment at MaxCyte with 0.78% Stake - TradingView
MaxCyte, Inc. (MXCT) holder River Global shifts 4.3% voting stake - Stock Titan
MXCT Q1 2026 Earnings: Narrower-Than-Expected Loss Drives 50.98% EPS SurpriseOperating Income Trends - vinanet.vn
Maxcyte Inc Azioni (MXCT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.29%
0.75%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):